In November 2020, the clinical study for treatment of acute viral pneumonia, facilitated by Beyond Air, a medical device and pharmaceutical company, is scheduled to commence. The study will consider enrollment for anyone infected with COVID-19 and pneumonia caused by any virus. The LungFit has been designated a medical device by the U.S. Food and Drug Administration (FDA) and filters Nitrus Oxide (NO2) from ambient air to deliver to the patient’s lungs. The machine would replace the need for high volume inventory for high pressure NO cylinders in hospitals in addition to other benefits for the reduced need to purge NO2. The study will be conducted in Israel and 90 randomized adults will be tested.
Read more here.
More on: News Regulatory